央广网永州7月11日消息 7月11日，在湖南省永州市江永县潇浦镇和兴村的电商直播间里，村民葛小梅正热情地向 全国网友推介家乡的香姜产品，屏幕上的订单数据不断跳动。这个曾经以传统农业为主的县城，如今正通过党建 引领与电商发展的深度融合，书写着乡村振兴的崭新篇章。 党建聚力：三级体系激活电商"人才引擎" 江永县以"电商街中心党委+功能型党支部+党员示范户"三级组织体系为核心，将23家省级电商示范企业、2000余 家直播商家纳入网格化管理，构建起"党建+电商"融合发展的新格局。 为破解人才短缺难题，该县出台电商人才创业扶持政策，派出"引才小分队"奔赴高校招贤纳士，吸引40余名电商 人才扎根创业。依托勾蓝瑶电商直播基地，常态化开展"我的乡村我主播"培训，累计培育电商人才200余名，5名 学员现场签约就业。 目前，全县电商企业和网店超2900家，电商产业直接从业人员达9000余人，形成"人才带产业、产业促振兴"的良 性循环。 数字赋能：三级物流网打通"最后一公里" 面对农产品销售瓶颈，江永县以数字化手段破局。建成87个农村电商服务站，整合"四通一达"、邮政等9家快递 资源，构建县乡村三级物流网，实现"快递进村"全覆盖。 ...

Core Viewpoint - The company, Sichuan Hebang Biotechnology Co., Ltd., is actively responding to regulatory inquiries regarding its 2024 annual report, particularly focusing on its mining operations and financial disclosures related to its mineral resources [1][2]. Mining Operations - The company holds a total of 40 mining rights, including 34 exploration rights and 6 mining rights, with an investment of approximately 620 million yuan for acquiring these rights [1][2]. - The mining sector has become a core contributor to the company's operating profits, with an expected profit contribution of 250 million yuan from phosphate rock sales in 2024 [1][2]. - The company employs a phased investment and rolling development strategy in its mining operations to manage risks and ensure cash flow [1][2]. Financial Performance - The company reported a total operating income of 8.547 billion yuan in 2024, a decrease of 3.13% year-on-year, with a net profit of 31 million yuan, down 97.55% from the previous year [1][12]. - The phosphate and salt mines have generated significant revenue, with phosphate sales expected to increase as construction projects are completed [5][12]. Investment Strategy - The company is strategically expanding into the mining sector, aligning with macroeconomic policies and market conditions, while leveraging its existing resources and personnel expertise [9][10]. - The company has established a robust management structure and has recruited over 180 new employees in the mining sector since 2024, enhancing its operational capabilities [8][9]. Risk Management - The company utilizes a joint venture model for overseas mining projects to mitigate risks and ensure compliance with local regulations [10][11]. - A comprehensive risk control framework is in place for both domestic and international mining operations, focusing on environmental protection, safety, and regulatory compliance [10][11]. Sales and Revenue Breakdown - The company has achieved significant sales in its mining operations, with phosphate and salt mines contributing to the majority of its revenue [5][12]. - The sales model primarily involves internal sales within the group, with a high collection rate of 90% on receivables [5][12].

Core Viewpoint - The company held a performance briefing to provide insights into its 2024 annual report and Q1 2025 results, addressing investor concerns and outlining strategies for navigating industry challenges and opportunities [1][2]. Performance Briefing Overview - The performance briefing was conducted on June 30, 2025, with key executives present to engage with investors and respond to their inquiries [2]. Industry Trends and Company Strategy - The retail pharmacy industry is undergoing significant transformation, with a closure rate of approximately 5.7% in 2024, leading to an accelerated industry consolidation [2][3]. - The company aims to leverage this consolidation by enhancing compliance, improving service quality, and expanding its market share through franchise and alliance models [2][3]. Profitability and Cost Management - The company is focused on cost reduction and efficiency improvements, targeting over 100 million yuan in cost savings for 2025 through various initiatives [3][4]. - A comprehensive reform of the procurement system is underway to enhance supply chain efficiency and align product offerings with consumer needs [4]. Expansion Plans - The company plans to open 1,000 new stores in 2025, primarily through franchise models, while also converting existing stores to franchises [5]. - The strategy includes focusing on existing markets to increase market share and profitability [5]. Diversification Opportunities - The company is pursuing service diversification, including chronic disease management and community health services, to enhance customer engagement and loyalty [6]. - Product diversification efforts are focused on expanding non-pharmaceutical categories, with a reported 9% year-over-year increase in sales of general food and personal care products in Q1 2025 [6]. Market Positioning and Competitive Advantage - The company emphasizes its competitive advantages in offline retail, including immediate service, professional advice, and health management services, particularly in lower-tier cities [7][8]. - The company has established a robust compliance framework to navigate regulatory challenges and maintain its market position [12]. ESG Initiatives - The company has integrated ESG principles into its operations, achieving a rating upgrade from BBB to A in the WindESG assessment for 2024 [10][11]. Financial Returns and Shareholder Engagement - The company has committed to distributing at least 50% of its net profit as cash dividends from 2024 to 2026, reflecting a strong commitment to shareholder returns [13][17]. - Cumulative cash dividends since its IPO amount to 2.069 billion yuan, demonstrating a consistent return to investors [17]. Franchise and Alliance Business Development - As of Q1 2025, the company has established 5,408 franchise stores and over 21,000 alliance stores, with significant growth in alliance business sales [14].

与此同时，东阳光药在创新药研发、BD合作以及AI技术应用等领域的积极探索与突破，更为其未来发 展注入强劲动力。 拟整合旗下医药资产赴港上市 与常规IPO不同，东阳光药本次递表港交所，将以介绍形式在香港上市。根据招股书，东阳光药持有港 股上市公司东阳光长江药业51.41%股权，东阳光药拟通过吸收合并方式将子公司东阳光长江药业私有 化，并将根据换股比率向全体换股股东发行H股，作为换股的对价，该发行方式不涉及新股发行与资金 募集。东阳光长江药业最终将注销。 东阳光药此举，旨在整合两大医药资产。其在招股说明书中表示，通过合并，东阳光药此举，旨在整合 两大医药资产。其在招股说明书中表示，东阳光药通过合并整合医药资产，打造集研发、生产、商业化 于一体的综合性制药公司，以创新与国际化战略整合境内外销售渠道，构建广泛销售网络，提升综合效 率，实现长期可持续的韧性增长。 目前，在医药领域，东阳光药凭借从原料药到制剂的完整生产线，构建起多元且强大的业务矩阵。 在抗感染儿科线，东阳光药以全球最大奥司他韦生产基地生产的明星产品可威（磷酸奥司他韦）占据儿 科流感治疗市场重要地位，其全球奥司他韦生产基地规模、产量和出货量均居第一，一流的 ...

可孚医疗 20260629 摘要 可孚医疗聚焦康复辅助、医疗护理、健康监护、呼吸支持和中医理疗五 大业务板块，并通过聚焦高毛利单品及线上兴趣电商和品牌建设投入， 显著提升了毛利率和净利率。 2024 年可孚医疗推出股权激励计划，向 339 名激励对象授予 663 万股 限制性股票，并设定了 2024 年至 2026 年三个归属期的绩效考核目标， 旨在激励核心团队。 康复辅助业务板块中，贝贝佳品牌在 2024 年销售额突破 4 亿元，对公 司整体盈利能力提升有所助力。健耳听力通过并购整合德林听力等三家 企业，巩固了线下服务能力。 健耳听力 2024 年收入 2.73 亿元，同比增长近 38%，但仍处于战略投 入阶段。2025 年，公司计划提升健耳听力的经营质量，而非单纯扩张 店面数量，以逐步提升利润贡献。 可孚医疗与欧泰科技合作研发的免校准 CGM 产品于 2024 年 10 月上市， 具有 MOD 值低、形态轻便、价格相对较低等特点，有望提升市场竞争 力。 Q&A 可孚医疗在 2025 年第一季度收入和利润均出现下滑，其主要原因是什么？ 2025 年第一季度，可孚医疗的收入和利润均有所下滑，主要系公司对呼吸机 ...

据IDC数据，2025年第一季度印度前五大智能手机厂商（按出货量、市场份额排名）分别为vivo、三 星、OPPO、小米、realme；东南亚市场前五大智能手机厂商分别为三星、vivo、小米、OPPO、苹果； 而在巴西智能手机市场，前两大厂商分别为苹果、三星；另外，西欧市场前三大智能手机厂商分别为苹 果、三星、小米。 不过，IDC指出，AI技术应用、高端市场发展以及本地化生产等因素正推动市场正向增长。未来，由于 智能手机普及率提高，换机周期延长以及二手智能手机蚕食市场，预计增长将保持在低位。 据悉，西欧市场中，苹果搭载AI功能的iPhone 16e需求强劲，带动其出货量同比增长125.5%，800美元 以上设备出货量占比达78.4%，推动西欧中高端智能手机市场格局变化。在日本市场，苹果也凭借新品 及直销支持取得显著增长，出货量同比大增29.3%。 6月26日，国际数据公司IDC发布最新研究显示，2025年第一季度全球智能手机市场出货量总计3.01亿 台，同比增长仅0.4%。 值得一提的是，这份研究显示，2025年第一季度，在非发达国家/地区，由于库存过剩、消费需求疲软 和市场竞争加剧等原因，市场面临较大压力。 ...

Group 1 - The core viewpoint of the articles is that Zhangyue Technology (掌阅科技) and Youku are collaborating to launch a year-long writing competition aimed at discovering quality original stories and potential creators [1][2] - The writing competition will focus on four main themes: "urban emotions," "realism," "suspense adventure," and "innovation track" [1] - Youku will leverage its film and television resources to provide opportunities for the winning works to enter its IP evaluation system, prioritizing them for film adaptation [1][2] Group 2 - Zhangyue Technology aims to enhance its content ecosystem by integrating resources with Youku, creating a broader creative space and display platform for creators [2] - The CEO of Zhangyue Technology, Sun Kai, stated that the short drama business has become the company's largest business segment, emphasizing its importance in expanding content expression and optimizing user engagement [2] - The company is transitioning from a "digital reading platform" to a "multi-modal content production and operation platform in the AI era," indicating a strategic upgrade [2]

如果你问我，见过最差的产品经理是谁，那我会毫无疑问如果满足下面5点的产品经理，就属于最差的产品经理，分别是 1.一点都不会使用原型工具 提到原型，有一些工作多年的产品经理会认为原型工具并不重要，原型只是表达产品业务与功能逻辑即可，用手绘制也可以，显然我从亲身经历来看是错 误的。 即使再厉害的产品经理，你可以说他不在绘制每一个页面，但是其中的核心功能仍然需要页面、按钮之间跳转。甚至是需要有电子档化，方便下面的产品 经理或者其他同时进行二次流转与标记。如下是其手绘制的原型页面，可以看到手绘制的仍然缺乏页面逻辑与功能跳转的详细说明，就导致无法仔细的评 估研发成本。 如果只是嘴巴说，从不亲手用原型工具绘制的（原型工具可以是PPT等），这样的产品经理是不负责的，他至少没有考虑到技术实现成本与研发周期。 虽然最后产品的商业模式是赚钱的，但是其研发的周期会过长，导致迟迟达不到理想的用户满意度，最典型的例子就是曾经米聊和微信的时候，当时米聊 有大量用户后就扛不住高并发，而有QQ经验的微信显然就非常娴熟的提供了稳定的用户体验。 3.产品研发团队，一周才碰一次 还有一种最差的产品经理，就是对研发团队与研发流程摸不关系，可能一周才 ...

6月19日，由阅文旗下女频网文平台潇湘书院孵化的"筑梦岛"App，因AI生成内容存在低俗擦边问题、 危害未成年人身心健康，被上海市网信办约谈。 "筑梦岛"App是一款以AI陪伴为核心功能的应用，主要提供用户与虚拟AI角色的聊天互动服务。公开信 息显示，筑梦岛App目前由上海筑梦岛人工智能科技有限公司负责运营。2025年1月，"筑梦岛"已正式 独立运营，并完成新一轮融资。天眼查显示，这笔融资由商汤国香基金、阅文集团等战略投资方共同投 资，融资金额超1000万美元。 "网信上海"通报称，上海市网信办依法约谈"筑梦岛"App运营企业主要负责人，要求平台立即整改，健 全AI生成合成内容审核机制，提升技术把关能力，加强涉未成年人不良内容的整治清理，切实落实未 成年人网络保护义务。企业负责人表示，将按照约谈要求，对照问题举一反三、全面整改。 2024年，AI陪伴产品赛道因一桩悲剧事件被推至舆论风口——一位年仅14岁的男孩长期沉迷于某款AI 陪伴应用中的虚拟角色，最终在深夜扣动扳机，结束了自己的生命。该男孩的母亲随后将这款AI陪伴 产品背后的公司Character.AI告上法庭，要求其为小孩的自杀担责。这起事件也引发外界对 ...

证券代码：688079 证券简称：美迪凯 杭州美迪凯光电科技股份有限公司 关于续聘天健会计师事务所（特殊普通合伙）作为公司 2025 年度审计机构的议案 . 13 关于注册资本变更、取消监事会、废止《监事会议事规则》并修订《公司章程》的议 杭州美迪凯光电科技股份有限公司 为了维护全体股东的合法权益，确保杭州美迪凯光电科技股份有限公司 （以下简称"公司"）股东大会的正常秩序和议事效率，保证大会的顺利进行， 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司股东会 规则》以及《杭州美迪凯光电科技股份有限公司章程》（以下简称"《公司章 程》"）等相关规定，特制定本须知： 一、为确认出席大会的股东或其代理人或其他出席者的出席资格，会议工 作人员将对出席会议者的身份进行必要的核对工作，请被核对者给予配合。 二、出席会议的股东及股东代理人须在会议召开前 30 分钟到会议现场办理 签到手续，并请按规定出示证券账户卡、身份证明文件或企业营业执照/注册证 书复印件（加盖公章）、授权委托书等，上述登记材料均需提供复印件一份， 个人登记材料复印件须个人签字，法定代表人证明文件复印件须加盖公司公章， 经验证后领取会议资料 ...